FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308394400> ?p ?o ?g. }

• W4308394400 abstract "<h3>Background</h3> Checkpoint immunotherapies (CPI) have resulted in long lasting responses in subsets of cancer patients. Despite this, responses come with the risk of immune-related adverse events (irAEs) which can limit the overall benefit of CPI. Associations with response, such as the correlation between development of irAE and better overall survival (OS), are well characterized in clinical trials but less understood in standard of care settings with wide varieties of patient profiles. Thus, real-world evidence cohorts are integral to bridging the gap between clinical trials reports and clinical practice. The RADIOHEAD study is a pan-tumor, prospective cohort study of 1,200 individuals on standard of care first-line CPI treatment regimens aiming to identify drivers of irAEs and clinical response. <h3>Methods</h3> To capture a comprehensive profile of each patient, we prospectively collected blood samples and clinical features at pretreatment, early on treatment, and 6 and 12 month timepoints via case report forms and electronic medical records from 52 community oncology clinics across the United States. Patients who experienced irAEs had additional samples and clinical data collected at analogous time intervals from the irAE onset. Clinical data were structured and harmonized and unbiased statistical analysis was performed to identify clinical predictors of OS. <h3>Results</h3> A total of 3951 samples and associated clinical data points were collected over the course of participants’ treatment. Patients with any irAE (25%) had significantly longer OS in the pan-tumor cohort (n=1061, HR=0.4, 95% CI=[0.3, 0.6]). The association between irAE and survival held in the largest tumor sub cohorts, non-small cell lung cancer (NSCLC) (N = 397) and melanoma (N = 128), when adjusting for age, and in multvariable analysis. Patients who reported already taking steroids at the time of their pretreatment blood draw had significantly shorter survival than those who did not (HR=1.5 [1.2, 2]); this association appeared more pronounced in patients taking systemic steroids. Comparing NSCLC and melanoma to all other tumor types in this standard of care dataset, patients with melanoma had significantly longer (HR=0.4 [0.3,0.6]) OS. <h3>Conclusions</h3> Results from this cohort study of standard of care patients support previously identified variables associated with CPI response. In the future, the potential for molecular profiling of samples collected in the RADIOHEAD cohort provides an opportunity to elucidate the potential mechanistic link between irAE and clinical response to CPI, as well as identify clinically actionable mechanisms for immunotherapy resistance via integrated analyses of multi-omic datasets to be generated from longitudinal patient samples. <h3>Acknowledgements</h3> Juvenile Diabetes Research Foundation The Leona M. and Harry B. Helmsley Charitable Trust Bristol Myers Squibb XCancer Patients who participated in the study <h3>References</h3> Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. <i>Nat Commun.</i> 2020;<b>11</b>:3801. https://doi.org/10.1038/s41467-020-17670-y Pasello G, Pavan A, Attili I, Bortolami A, Bonanno L, Menis J, Conte P, Guarneri V. Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer. <i>Cancer Treat Rev</i>. 2020;<b>87</b>:102031. doi: 10.1016/j.ctrv.2020.102031. Epub 2020 May 16. PMID: 32446182. Das S, Johnson DBImmune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. <i>Journal for ImmunoTherapy of Cancer.</i> 2019;<b>7</b>:306. doi: 10.1186/s40425-019-0805-8 Maher VE, Fernandes LL, Weinstock C, Tang S, Agarwal S, Brave M, Ning YM, Singh H, Suzman D, Xu J, Goldberg KB, Sridhara R, Ibrahim A, Theoret M, Beaver JA, Pazdur R. Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody. <i>J Clin Oncol.</i> 2019;<b>37</b>(30):2730–2737. doi: 10.1200/JCO.19.00318. Epub 2019 May 22. PMID: 31116675." @default.
• W4308394400 created "2022-11-11" @default.
• W4308394400 creator A5009517654 @default.
• W4308394400 creator A5011274637 @default.
• W4308394400 creator A5021532414 @default.
• W4308394400 creator A5022032234 @default.
• W4308394400 creator A5022333320 @default.
• W4308394400 creator A5032104940 @default.
• W4308394400 creator A5040207559 @default.
• W4308394400 creator A5045990142 @default.
• W4308394400 creator A5052770346 @default.
• W4308394400 creator A5057774741 @default.
• W4308394400 creator A5072482126 @default.
• W4308394400 date "2022-11-01" @default.
• W4308394400 modified "2023-09-27" @default.
• W4308394400 title "1256 Relationships between irAEs and checkpoint inhibitor response in RADIOHEAD: a large prospective pan-tumor cohort of standard-of-care patients with clinical annotation, molecular and immune profiling" @default.
• W4308394400 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1256" @default.
• W4308394400 hasPublicationYear "2022" @default.
• W4308394400 type Work @default.
• W4308394400 citedByCount "0" @default.
• W4308394400 crossrefType "proceedings-article" @default.
• W4308394400 hasAuthorship W4308394400A5009517654 @default.
• W4308394400 hasAuthorship W4308394400A5011274637 @default.
• W4308394400 hasAuthorship W4308394400A5021532414 @default.
• W4308394400 hasAuthorship W4308394400A5022032234 @default.
• W4308394400 hasAuthorship W4308394400A5022333320 @default.
• W4308394400 hasAuthorship W4308394400A5032104940 @default.
• W4308394400 hasAuthorship W4308394400A5040207559 @default.
• W4308394400 hasAuthorship W4308394400A5045990142 @default.
• W4308394400 hasAuthorship W4308394400A5052770346 @default.
• W4308394400 hasAuthorship W4308394400A5057774741 @default.
• W4308394400 hasAuthorship W4308394400A5072482126 @default.
• W4308394400 hasBestOaLocation W43083944001 @default.
• W4308394400 hasConcept C126322002 @default.
• W4308394400 hasConcept C143998085 @default.
• W4308394400 hasConcept C188816634 @default.
• W4308394400 hasConcept C195910791 @default.
• W4308394400 hasConcept C197934379 @default.
• W4308394400 hasConcept C201903717 @default.
• W4308394400 hasConcept C535046627 @default.
• W4308394400 hasConcept C71924100 @default.
• W4308394400 hasConcept C72563966 @default.
• W4308394400 hasConceptScore W4308394400C126322002 @default.
• W4308394400 hasConceptScore W4308394400C143998085 @default.
• W4308394400 hasConceptScore W4308394400C188816634 @default.
• W4308394400 hasConceptScore W4308394400C195910791 @default.
• W4308394400 hasConceptScore W4308394400C197934379 @default.
• W4308394400 hasConceptScore W4308394400C201903717 @default.
• W4308394400 hasConceptScore W4308394400C535046627 @default.
• W4308394400 hasConceptScore W4308394400C71924100 @default.
• W4308394400 hasConceptScore W4308394400C72563966 @default.
• W4308394400 hasLocation W43083944001 @default.
• W4308394400 hasOpenAccess W4308394400 @default.
• W4308394400 hasPrimaryLocation W43083944001 @default.
• W4308394400 hasRelatedWork W2042664817 @default.
• W4308394400 hasRelatedWork W2109699253 @default.
• W4308394400 hasRelatedWork W2518309888 @default.
• W4308394400 hasRelatedWork W2750095015 @default.
• W4308394400 hasRelatedWork W3116131585 @default.
• W4308394400 hasRelatedWork W3176033318 @default.
• W4308394400 hasRelatedWork W3188792418 @default.
• W4308394400 hasRelatedWork W3203363473 @default.
• W4308394400 hasRelatedWork W4254169278 @default.
• W4308394400 hasRelatedWork W4289888068 @default.
• W4308394400 isParatext "false" @default.
• W4308394400 isRetracted "false" @default.
• W4308394400 workType "article" @default.